Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting

May 21, 2024

https://www.globenewswire.com/news-release/2024/05/21/2885569/0/en/Positive-Statistically-Significant-Phase-2-Clinical-Trial-Results-of-Biodexa-s-Newly-licensed-eRapa-in-Familial-Adenomatous-Polyposis-FAP-Scheduled-for-Presentation-at-the-2024-Dig.html

May 21, 2024

Biodexa Pharmaceuticals PLC
(“Biodexa” or the “Company”)

Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the
2024 Digestive Disease Week Annual Meeting

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.